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Aims Chronic pre-treatment with statins may reduce mortality and morbidity in patients experiencing acute coronary
syndromes (ACS), but mechanisms accounting for these findings are not completely understood.
...................................................................................................................................................................................................
Methods
and results
The optical coherence tomography (OCT)-Formidable registry retrospectively enrolled 285 consecutive patients
with ACS undergoing OCT in 9 European centres. Mean age was 60.4 ± 12.8 years, 148 (51.9%) patients had
hyperlipemia, 45 (15.8%) diabetes mellitus and 142 (49.8%) presented with ST Segment Elevation Myocardial
Infarction (STEMI). Patients were stratified according to statin prescription: 150 (52.6%) were on chronic pre-
treatment with statins before ACS and were more likely to present with non-ST segment elevation acute coronary
syndromes (NSTE-ACS) at admission (111, 74%) rather than STEMI, while the opposite was observed for patients
not on statins. The primary end-point of ruptured plaque at OCT occurred significantly less frequently in the
patients on chronic pre-treatment with statins [odds ratio (OR) 0.375, 95% confidence interval (CI) 0.185–0.759,
P= 0.006]. The secondary end-point of thin-cap fibro-atheroma (TCFA) at any site was significantly less frequent in
the statin group (OR 0.423, 95%CI 0.213–0.840, P= 0.014). No differences were observed for the secondary end-
point of not-ruptured TCFA as the culprit lesion. Pre-specified sensitivity analysis was conducted according to the
pattern of ACS: the reported differences were confirmed for NSTE-ACS patients, with a trend towards less plaque
rupture and a significant reduction of TCFA at any site with statins, but not for STEMI.
* Corresponding author. Tel: þ39 0116336022; Fax: þ39 0116336015. E-mail: sebastiano.gili@gmail.com
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author 2017. For permissions, please email: journals.permissions@oup.com.
European Heart Journal - Cardiovascular Imaging (2017) 0, 1–8
doi:10.1093/ehjci/jex102
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
...................................................................................................................................................................................................
Conclusions Chronic pre-treatment with statins is associated with a reduced prevalence of ruptured plaques in patients present-
ing with ACS, particularly in those with NSTE-ACS. Statins bear hence the potential to reduce morbidity during
the acute phase of ACS.
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Introduction
Statins have been shown to positively reduce cardiovascular (CV)
morbidity and mortality in many settings by lowering the rate of CV
events in both primary and secondary prevention.1–3 Moreover,
patients chronically treated with statins may experience more favour-
able outcomes when experiencing acute coronary syndromes (ACS)
compared with patients starting the treatment after the event.4–6
The mechanisms contributing to the prognostic improvement related
to statins in this latter situation are not completely understood.
Optical coherence tomography (OCT) is an intracoronary imaging
technique, which can qualitatively describe and precisely define fea-
tures of different atherosclerotic plaques. OCT and intravascular ultra-
sound studies have demonstrated that chronic treatment with statins
reduce the atherosclerotic burden and the prevalence of plaques with
a higher risk of destabilization.7,8 In the ACS setting OCT may identify
the culprit lesions and define their features, particularly the presence
of thrombus, ruptured plaques or eroded thin-cap fibro-atheromas
(TCFA), which may differently impact the long-term prognosis.9
To date, there has been little data detailing the effects of statins on
atherosclerotic plaques during the acute phase of ACS. Therefore,
the present study was conducted with the aim to assess if chronic
treatment with statins prior to an ACS may reduce the incidence of
ruptured plaques.
Methods
The OCT-FORMIDABLE is a multicentre retrospective registry including
consecutive patients presenting with ACS and undergoing OCT evaluation
of the culprit and non-culprit plaques between January 2014 and October
2015 in nine centres (‘AOU Citta della Scienza e della Salute’, Turin, Italy; ‘SG
Bosco Hospital’, Turin, Italy; ‘Policlinico Gemelli’, Rome, Italy; ‘Policlinico
Umberto I’, Rome, Italy; ‘Ferrarotto Hospital’, Catania, Italy; ‘Ospedale
Maggiore della Carita’, Novara, Italy; ‘Centre Hospitalier Universitaire de
Clermont-Ferrand’, Clermont-Ferrand, France; ‘Hoˆpitaux de Marseille’,
Marseille, France; ‘Hippokration Hospital’, Athens, Greece). Patients with
poor image quality, incomplete pullback or missing data were excluded. Of
note, the choice to perform OCT was left to the operator’s decision.
Informed consent was obtained from all patients. The study was
approved by the local Ethics Committees and registered on
ClincalTrials.gov (NCT02486861). Clinical and OCT data were recorded,
as well as medications taken on admission and at hospital discharge. For
the index admission, diagnosis of ACS was adjudicated according to ESC
guidelines (STEMI, ST segment elevation myocardial infarction and NSTE-
ACS, non-ST segment elevation ACS, including non-ST segment eleva-
tion MI and unstable angina).10,11
Diabetes mellitus was defined according to the American Diabetes
Association criteria12 [fasting blood glucose >126 mg/dL or treated diabe-
tes mellitus (intake of a diabetic diet or oral hypoglycaemic agents);
hyperlipemia according to the current ESC guidelines (i.e., low-density lip-
oprotein cholesterol above the reference values based on the estimated
CV risk) or treated hyperlipemia; hypertension as systolic blood
pressure >140 mmHg and/or diastolic blood pressure >90 mmHg or
treated hypertension].
For the purpose of this sub-analysis, patients were stratified according
to the prescription of statins prior to the index event. A 6-month follow-
up was planned for each patient. Follow-up was performed by clinical
outpatient visit or telephone contact.
Invasive treatment and clinical data
collection
All patients were treated according to current ESC guidelines.
Particularly, aspirin and clopidogrel or prasugrel or ticagrelor were
administered upon admission to the Emergency Department. Coronary
angiographies and percutaneous coronary interventions were performed
through a radial or femoral access according to operator’s preference;
heparin or bivalirudine was used according to local protocols. NSTE-ACS
patients received fondaparinux or enoxaparin as well. Manual thrombus
aspiration was performed according to operator’s decision.10,11
OCT procedure
A 0.014-inch guidewire was placed distally in the target vessel and an
intracoronary injection of nitroglycerin was performed. Frequency
domain OCT (FD-OCT) images were acquired by a commercially avail-
able system (C7 System, LightLab Imaging Inc/St Jude Medical, Westford,
MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/
St Jude Medical, Westford, MA), which was advanced to the culprit lesion.
The FD-OCT run was performed using the integrated automated pull-
back device. In case of STEMI, OCT was performed after vessel reopen-
ing and thrombus aspiration. During image acquisition, coronary blood
flow was replaced by continuous flushing of contrast media directly from
the guiding catheter with a power injector in order to create a virtually
blood-free environment.
OCT image analysis
OCT image analysis was performed at each treating center unblinded to
the clinical features of the patients. Centralized, offline review of the
images was performed by a single operator (MI) who was blinded to
patients’ clinical features and particularly to statin therapy. Culprit lesion
was identified by means of angiography, electrocardiographic ST-segment
alterations, and/or regional wall motion abnormalities on echocardio-
graphic assessment.
Plaque rupture was defined as the presence of fibrous cap discontinu-
ity leading to a communication between the inner (necrotic) core of the
plaque and the lumen. Plaque rupture also included fibrous cap disruption
detected over a calcified plaque characterized by protruding calcification,
superficial calcium, and the presence of substantive calcium proximal or
distal to the lesion. TCFA was defined as cap thickness < 65 nm.
Fibrocalcific, fibrotic plaque, lipid component or macrophage infiltration
were recorded. OCT lesions were defined according to International
2 S. Gili et al.
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Working Group for Intravascular Optical Coherence Tomography
(IWG-IVOCT) consensus standards.13
Study end-points
The primary endpoint was the presence of ruptured plaque at OCT.
Secondary end-points were the presence of TCFA without signs of rup-
ture as the culprit lesion, TCFA at any site and MACE (death, myocardial
infarction, target vessel revascularization) at the 6-month follow-up. A
pre-specified sensitivity analysis was conducted according to the clinical
presentation of ACS (STEMI vs. NSTE-ACS).
Statistical analysis
Categorical variables are reported as count and percentages. Continuous
variables are reported as mean and standard deviation or interquartile
range (IQR). Gaussian or non-Gaussian distribution was evaluated by
Kolmogorov-Smirnoff test. T-test was used to assess differences between
parametric and continuous variables. Mann–Whitney U test was used to
assess non-parametric variables. Chi-square test and Fisher exact test
were used to assess categorical variables. Multivariate assessment of
study outcomes was performed by logistic regression or Cox regression
analysis to account for potential confounding. A model including all cova-
riates associated with chronic statin prescription with a P-value < 0.10
was built for each study outcome. Results were reported as odds-ratios
(OR) or hazard ratios (HR), as appropriate.14 Sensitivity analysis was per-
formed for clinical presentation (STEMI vs. NSTE-ACS). A two-sided
P-value <0.05 was considered statistically significant. All analyses were
performed with SPSS 21.0 (IBM, Armonk, NY, USA).
Results
A total of 285 patients were included in this study. The mean age was
60.4 ± 12.8 years and 58 (20.4%) were female. From the total patient
population, 164 (57.5%) had hypertension, 148 (51.9%) had hyperli-
pemia and 45 (15.8%) had diabetes mellitus (Table 1). Clinically, 142
(49.8%) patients presented with STEMI while 143 (50.2%) patients
presented with NSTE-ACS. Patients presenting with NSTE-ACS
were older and had a greater burden of CV risk factors compared to
those presenting with STEMI (Tables 2 and 3).
Left anterior descending coronary artery was the target vessel in
178 (62.5%) patients. As expected, a low number of patients with LM
lesions were included (13, 4.6%). A stent was implanted in the major-
ity of patients (247, 86.3%; 125, 43.9%, second generation drug-
eluting stents).
At OCT analysis (Figure 1, Table 2), a ruptured plaque was recog-
nized as the culprit lesion in 186 (65.3%) cases and TCFA without
signs of rupture in 22 (7.7%). Plaque rupture was associated with a
higher prevalence of TCFA at any site, a thinner minimum fibrous-
cap thickness and other features of higher risk plaques (see
Supplementary data online, Table S1).
One hundred and fifty patients (52.6%) were on statin treatment
prior to hospital admission. As shown in Table 1, patients on statin
treatment were older, more frequently female and presented a
higher prevalence of CV risk factors (except smoking). Beta-blockers,
angiotensin converting enzyme inhibitors (ACE-I) or angiotensin
receptor blockers (ARB) and aspirin were prescribed more fre-
quently to patients on statins. At admission, patients treated with sta-
tins were more likely to present with NSTE-ACS rather than STEMI,
while the opposite pattern was encountered for patients not on
statins. Chronic treatment with statins was associated at univariate
analysis with a lower incidence of ruptured plaques, TCFA rupture,
TCFA at any site and residual thrombus (Figure 1, Table 2). Patients
previously treated with statins presented, moreover, a thicker fibrous
cap (Table 2).
A multivariate assessment by logistic regression was conducted to
take into account potential confounding factors. Based on this analy-
sis, statins were independently associated with a lower rate of the pri-
mary end-point of plaque rupture [OR 0.375, 95% confidence
interval (CI) 0.185–0.759, P¼ 0.006; Figure 2] and the secondary
end-point of TCFA at any site (OR 0.423, 95%CI 0.213–0.840, P =
0.014, see Supplementary data online, Figure S1). No differences
were detected pertaining not-ruptured TCFA at the culprit site (see
Supplementary data online, Figure S2).
NSTE-ACS vs. STEMI patients
Among patients presenting with NSTE-ACS (Table 3), those already
on statin treatment presented with a higher prevalence of hyperlipe-
mia and previous prescription of aspirin and beta-blockers. Plaque
rupture, TCFA and TCFA rupture were less frequent in patients on
treatment with statins, even if these differences failed to reach statisti-
cal significance (Figure 3). Patients from the statin group presented a
thicker fibrous cap, even if difference did not reach statistical signifi-
cance (see Supplementary data online, Table S2).
Among STEMI patients (Table 4), those previously treated with sta-
tins were older, and had a higher prevalence of hyperlipemia and dia-
betes. Statin treatment was significantly associated with prescription
of aspirin, beta-blockers, ACE-I/ARB. No significant differences were
reported pertaining to study end-points (Figure 3). Supplementary
data online, Tables S2 and S3 report the complete results of the OCT
analysis stratified by clinical presentation.
Effect of statins on plaque rupture was assessed in both NSTE-
ACS and STEMI patients by logistic regression analysis. In NSTE-ACS,
previous treatment with statins showed a trend towards an inde-
pendent association with the absence of ruptured plaque at OCT
(OR 0.410, 95%CI 0.162–1.038, P = 0.060) in a model including CV
risk factors and drugs (Figure 4). In the same patients, statins showed
a protective effect towards detection of TCFA in any vessel (OR
0.372, 95%CI 0.147–0.939, P¼ 0.036), while no significant relation-
ship was reported for TCFA without signs of plaque rupture (see
Supplementary data online, Figures S3 and S4). Interestingly, in these
patients, plaque rupture was independently associated with an
increased rate of MACE after 6-months follow-up (HR 3.755, 95%CI
1.253–11.250, P = 0.018).
In contrast, STEMI patients with previous statin treatment did not
show a significant relationship with the presence of plaque rupture
nor TCFA at OCT (see Supplementary data online, Figure S5–S7)
after controlling for possible confounding factors.
Discussion
The main findings of our study are:
(1) Chronic pre-treatment with statins may reduce the incidence of pla-
que rupture in patients presenting with ACS
(2) The protective effect of chronic pre-treatment with statins is prob-
ably more accentuated in patients presenting with NSTE-ACS, as
Statin therapy and plaque rupture at optical coherence tomography (OCT) 3
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..these patients trended towards significantly lower prevalence of pla-
que rupture and significantly less TCFA at any site.
Prognostic benefits relating to statin therapy are usually mediated by
a reduction in the incidence of CV events, both in the primary and
secondary prevention settings.3 Even when they ‘fail’ to prevent CV
events, as in the case of ACS, statins have been shown to exert pro-
tective effects as patients chronically treated with statins before
experiencing ACS have reported more favourable outcomes at both
short and long-term follow-up.4–6 Our finding that statins are associ-
ated with a lower incidence of plaque rupture could partially explain
the mechanisms of this protective effect. As highlighted by previous
anatomo-pathological and OCT studies, culprit lesions during ACS
may present various features, which are associated with different clin-
ical presentations (i.e., STEMI vs. NSTE-ACS) and outcomes.15–17
Plaque rupture is often encountered in more severe clinical presenta-
tions of ACS and relates to higher morbidity and mortality as com-
pared with milder lesions like erosion of TCFA.18 Thrombi are more
often found in association with plaque rupture and are also associated
with poorer prognostic outcome.19 Statins have been reported to
reduce atherosclerotic burden and to stabilize atherosclerotic pla-
ques in patients with stable, chronic, ischaemic heart disease.
Previous OCT studies have shown a reduction in the total plaque
volume and a relative increase of fibrotic and fibrocalcifique plaques
as compared with lipidic macrophage rich and necrotic-core plaques,
....................................................................................................................................................................................................................
Table 1 Baseline features of the study population, stratified according to previous treatment with statins
Overall Previously not treated with statins Previously treated with statins P
(n5 285) (n5 135) (n5 150)
Age (years) 60.4 ± 12.8 56.5 ± 12.6 64.0 ± 12.0 <0.001
Female 58 (20.4) 20 (14.8) 38 (25.3) 0.028
Hypertension 164 (57.5) 60 (44.4) 104 (69.3) <0.001
Hyperlipemia 148 (51.9) 48 (35.6) 100 (66.7) <0.001
Diabetes mellitus 45 (15.8) 8 (5.9) 37 (24.7) <0.001
Smoker 175 (61.4) 90 (66.7) 85 (56.7) 0.083
STEMI 142 (49.8) 103 (72.5) 39 (27.5) <0.001
NSTE-ACS 143 (50.2) 32 (22.4) 111 (77.6) <0.001
ACE-I/ARB 116 (40.7) 26 (19.3) 90 (60.0) <0.001
Beta-blockers 122 (42.8) 19 (14.1) 103 (68.7) <0.001
Aspirin 143 (50.2) 25 (18.5) 118 (78.7) <0.001
Left main coronary 13 (4.6) 7 (5.2) 6 (4.0) 0.632
Left anterior descending coronary 178 (62.5) 75 (55.6) 103 (68.7) 0.022
Circumflex coronary 81 (28.4) 29 (21.5) 52 (34.7) 0.014
Right coronary 129 (45.3) 67 (49.6) 62 (41.3) 0.145
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; STEMI, ST-segment elevation myocardial infarction; NSTE-ACS, non-ST segment
elevation acute coronary syndromes.
Values reported as counts and percentage, unless differently stated.
....................................................................................................................................................................................................................
Table 2 OCT findings in the overall study population, stratified by previous chronic therapy with statins
Overall (n¼285) Previously not treated
with statins (n¼135)
Previously treated
with statins (n¼150)
P
Residual thrombus 83 (46.4) 58 (48.7) 25 (41.7) 0.37
Plaque rupture 186 (65.3) 103 (76.3) 83 (55.3) <0.001
Not ruptured TCFA 22 (7.7) 7 (5.2) 15 (10.0) 0.128
TCFA at rupture site 144 (50.5) 89 (65.9) 55 (36.6) <0.001
TCFA other site 54 (26.2) 31 (24.8) 23 (28.4) 0.567
TCFA at any site 174 (61.1) 97 (71.9) 77 (51.3) <0.001
Minimum fibrous cap thickness (mm) 75.5 ± 49.9 67.1 ± 47.5 83.1 ± 50.9 0.007
Fibrocalcifique plaques 89 (31.2) 33 (24.4) 56 (37.3) 0.019
Fibrous plaques 145 (50.9) 44 (32.6) 101 (67.3) <0.001
Lipid component 238 (83.5) 124 (91.9) 114 (76.0) <0.001
Necrotic core with macrophage infiltration 96 (33.8) 32 (23.7) 64 (43.0) 0.001
TCFA, thin-cap fibro-atheroma.
Values reported as counts and percentage, unless differently stated.
4 S. Gili et al.
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which present a higher risk of destabilization.7,17,20,21 An increase in
the thickness of fibrous cap with statins has been previously reported
and was also observed in our study.22 The positive effect of statins on
plaque remodelling has been shown to be a class effect observed for
low, moderate, or high statin doses, even if a dose-response relation-
ship has been demonstrated with more pronounced reductions for
higher doses.22 These effects are sustained mainly by the so-called
‘pleiotropic effects’ of statins, which are mediated by various mecha-
nisms, including an anti-inflammatory effect, which may contribute to
‘stabilize’ atherosclerotic plaques.23 Our results suggest that the plei-
otropic effects of statins may also have a positive influence in the
acute phase of ACS, by limiting the occurrence of plaque rupture.
In our study, patients on statin therapy presented with a higher CV
risk profile and, thus, a higher risk of plaque rupture.15 Additionally,
these patients were more likely to be treated with ACE-I or ARB,
aspirin and beta-blockers. Based on our multivariate models, statins
exerted their protective effects on plaque rupture in spite of the
increased CV risk of these patients and independently from the other
CV drugs prescribed. Interestingly, ACE-I/ARB were also independ-
ently associated with a protective effect against plaque rupture in our
global population. This is possibly due to the anti-inflammatory effect,
which has been described also for this drug class.24
....................................................................................................................................................................................................................
Table 3 Baseline features of patients presenting with non-ST segment elevation acute coronary syndromes, stratified
according to the previous chronic prescription of statins
Overall (n5 143) Previously not treated
with statins (n5 32)
Previously treated
with statins (n5 111)
P
Age (years) 64.70 ± 11.9 62.4 ± 11.3 65.4 ± 12.1 0.208
Female 37 (25.9) 8 (25.0) 29 (26.1) 0.898
Hypertension 109 (76.2) 21 (65.6) 88 (79.3) 0.110
Hyperlipemia 89 (62.2) 11 (34.4) 72 (64.9) <0.001
DM 31 (21.7) 3 (9.4) 28 (25.2) 0.086
Smokeer 78 (54.5) 18 (56.3) 60 (54.1) 0.826
LVEF 52.3 ± 9.9 54.2 ± 10.8 51.8 ± 9.6 0.242
ACE-I/ARB 87 (60.8) 15 (46.9) 72 (64.9) 0.066
Beta-blockers 89 (62.2) 4 (43.8) 75 (67.6) 0.014
Aspirin 107 (74.8) 17 (53.1) 90 (81.1) 0.001
Left main coronary 8 (5.6) 2 (6.3) 6 (5.4) 0.855
Left anterior descending coronary 103 (72.0) 25 (78.1) 78 (70.3) 0.383
Circumflex coronary 51 (35.7) 13 (40.6) 38 (34.2) 0.506
Right coronary 56 (39.2) 11 (34.4) 45 (40.5) 0.529
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; LVEF, left ventricle ejection fraction.
Values reported as counts and percentage, unless differently stated.
Figure 1 Prevalence at OCT analysis of plaque rupture, not-
ruptured TCFAs and TCFA at any site in the overall study popula-
tion, stratified according the previous treatment with statins. TCFA,
thin-cap fibro-atheroma.
Figure 2 Independent predictors of plaque rupture by logistic
regression analysis in the overall study population (ACE-I/ARB,
angiotensin converting enzyme inhibitors/angiotensin receptor
blockers).
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A strong trend towards a reduction in the incidence of plaque
rupture was observed for NSTE-ACS patients and not for STEMI
patients even after controlling for possible confounding factors.
NSTE-ACS is an entity which encompasses a wide variety of clinical
presentations, ranging from unstable angina to non-ST elevation
myocardial infarction which are sustained by a variety of
pathophysiological substrates such as plaque rupture, white throm-
bus, eroded TCFA, and haemorrhagic plaques. STEMI presentation is
more ‘mono-dimensional’ and is generally mediated by the formation
of a red-thrombus over a ruptured plaque.17,25 Plaque rupture was
encountered in 78.9% of STEMI patients and in 51.7% of NSTE-ACS
patients in our report. Moreover, NSTE-ACS patients presented
with a higher prevalence of comorbidities and CV risk factors includ-
ing hyperlipemia and diabetes mellitus. In this scenario, it is plausible
that statins may exert a more incisive protective effect in NSTE-ACS
rather than STEMI patients. However, the differential effect of statins
between NSTE-ACS and STEMI observed in our study may also be
due to sample size and statistical power issues. Only 39 patients in
the STEMI group were not on statins at the time of the event. Plaque
rupture was the culprit lesion in more than 80% of the STEMI patients
and a lower prevalence of plaque rupture and TCFA, even if non-
significant, was also observed for STEMI patients. Moreover, since
duration, dosage and effectiveness of statin therapy were not
assessed in the present analysis, the influence of statin therapy inten-
sity cannot be excluded from this finding. However, if a true lower
preventive efficacy of statins against plaque rupture had to be con-
firmed, we should suppose that a plaque-destabilization process,
scarcely responsive to statin therapy, may occur in STEMI patients, as
opposed to NSTE-ACS patients.
Beyond a reduction in plaque rupture, our results showed that, in
patients with NSTE-ACS, those on statins presented a lower preva-
lence of TCFA at any site, with a trend towards a thicker fibrous cap.
TCFA are atherosclerotic lesions with a high propensity towards
destabilization. Patients with a high TCFA burden are at increased
risk of progression of coronary artery disease, plaque rupture and
CV events.21,26 The protective effect of the chronic treatment with
statins in the acute phase of ACS could be thus, at least partially,
mediated by the reduction of these high-risk features of atheroscler-
otic lesions occurring before the ACS. However, statins have been
Figure 3 Prevalence at OCT analysis of plaque rupture, not-
ruptured TCFAs and TCFA at any site in patients with non-ST seg-
ment elevation acute coronary syndromes (NSTE-ACS, left panel)
and with ST-segment elevation myocardial infarction (STEMI, right
panel), stratified according the previous treatment with statins
(TCFA, thin-cap fibro-atheroma).
....................................................................................................................................................................................................................
Table 4 Baseline features of patients presenting with ST-segment elevation myocardial infarction, stratified according
to the previous chronic prescription of statins
Overall (n5 142) Previously not treated
with statins (n5103)
Previously treated
with statins (n539)
P
Age 56.10 ± 12.2 54.7 ± 12.5 60 ± 10.7 0.020
Female 21 (14.8) 12 (11.7) 9 (23.1) 0.087
Hypertension 55 (38.7) 39 (37.9) 16 (41.0) 0.730
Hyperlipemia 59 (41.5) 37 (35.9) 22 (56.4) 0.027
DM 14 (9.9) 5 (4.9) 9 (23.1) 0.001
Smoker 97 (68.3) 72 (69.9) 25 (64.1) 0.507
LVEF 54.5 ± 7.6 54.4 ± 7.7 54.8 (7.6) 0.779
ACE-I/ARB 29 (20.4) 11 (10.7) 18 (46.2) <0.001
Beta-Blockers 33 (23.2) 5 (4.9) 28 (71.8) <0.001
Aspirin 36 (25.4) 8 (7.8) 28 (71.8) <0.001
Left Main coronary 5 (3.5) 5 (4.9) 0 (0.0) 0.161
Left Anterior Descending coronary 75 (52.8) 50 (48.5) 25 (64.1) 0.097
Circumflex coronary 30 (21.1) 16 (15.5) 14 (35.9) 0.008
Right coronary 73 (51.4) 56 (54.3) 17 (43.6) 0.391
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; LVEF, left ventricle ejection fraction.
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.
demonstrated to exert anti-inflammatory and plaque-stabilizing
effects with positive prognostic repercussions also when adminis-
tered in the acute phase of ACS.27 It is plausible that our results
depend on a combination of chronic and acute effects of statins,
even if our data do not allow discriminating between these two
actions.
The reduction of plaque rupture in NSTE-ACS associated with sta-
tin treatment may have relevant clinical repercussions. As previously
reported in literature, as well in our study, plaque rupture in ACS
relates to a worse long-term outcome.18 This result may partly be
explained by the higher prevalence of TCFA observed in our study in
patients with plaque rupture. As TCFA relates with a higher risk of
unfavourable CV events, it is plausible that the reduction of TCFA
induced by statins prior to the ACS may exert protective effects also
after the ACS. In any case, our data suggest that, when appropriately
prescribed, statins bear the potential to exert long-term beneficial
effects even in patients in where they failed to prevent a CV event, in
this case, in the form of ACS.
Finally, our results confirm that OCT may be a useful tool for the
assessment of the effectiveness of lipid lowering and anti-
atherosclerotic treatments. Future studies and randomized con-
trolled trials assessing the effects of such treatments in the ACS
setting should include OCT, as this intracoronary imaging system
could provide valuable information on parameters with potential
prognostic repercussions.
Limitations
The study was not an all-comers study, as the choice to perform
OCT was left to the operator’s preferences and the centres’ proto-
cols, thus, potential selection bias may have been introduced. Images
were analysed and interpreted in each participating center. A single
operator reviewed all the images blinded to the patients’ status
regarding statins, but the study lacked a proper core-lab. Data on sta-
tin type, dosage, duration and LDL cholesterol values were not avail-
able for all patients and were thus not analysed. Finally, sub-group
analyses (NSTE-ACS vs. STEMI) were limited by the small sample
sizes of the two groups, and, for STEMI, by the low prevalence of
patients not on statins in this group.
Conclusions
Chronic treatment with statins is associated with reduced incidence
of plaque rupture detected by OCT in patients presenting with ACS,
with a potentially more marked effect in patients with NSTE-ACS. As
plaque rupture is associated with a worse prognostic outcome, our
results suggest that physicians should be aware of the importance of
statin therapy and prescribe this treatment whenever it is indicated,
both in the primary and in the secondary prevention setting.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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